80 related articles for article (PubMed ID: 26186480)
1. Trivalent ligands for CXCR4 bearing polyproline linkers show specific recognition for cells with increased CXCR4 expression.
Nomura W; Koseki T; Ohashi N; Mizuguchi T; Tamamura H
Org Biomol Chem; 2015 Aug; 13(32):8734-9. PubMed ID: 26186480
[TBL] [Abstract][Full Text] [Related]
2. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
3. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells.
Tanaka T; Nomura W; Narumi T; Masuda A; Tamamura H
J Am Chem Soc; 2010 Nov; 132(45):15899-901. PubMed ID: 20973474
[TBL] [Abstract][Full Text] [Related]
4. Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.
Nomura W; Aikawa H; Taketomi S; Tanabe M; Mizuguchi T; Tamamura H
Bioorg Med Chem; 2015 Nov; 23(21):6967-73. PubMed ID: 26453409
[TBL] [Abstract][Full Text] [Related]
5. High affinity CXCR4 inhibitors generated by linking low affinity peptides.
Zhang C; Huang LS; Zhu R; Meng Q; Zhu S; Xu Y; Zhang H; Fang X; Zhang X; Zhou J; Schooley RT; Yang X; Huang Z; An J
Eur J Med Chem; 2019 Jun; 172():174-185. PubMed ID: 30978562
[TBL] [Abstract][Full Text] [Related]
6. Detecting Cell Surface Expression of the G Protein-Coupled Receptor CXCR4.
Nevins AM; Marchese A
Methods Mol Biol; 2018; 1722():151-164. PubMed ID: 29264804
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
[TBL] [Abstract][Full Text] [Related]
9. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation.
Pello OM; Martínez-Muñoz L; Parrillas V; Serrano A; Rodríguez-Frade JM; Toro MJ; Lucas P; Monterrubio M; Martínez-A C; Mellado M
Eur J Immunol; 2008 Feb; 38(2):537-49. PubMed ID: 18200497
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR.
Toyama K; Kobayakawa T; Nomura W; Tamamura H
Chem Pharm Bull (Tokyo); 2018; 66(11):1083-1089. PubMed ID: 30381661
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.
Yang Y; Gao M; Zhang Q; Zhang C; Yang X; Huang Z; An J
Bioorg Med Chem; 2016 Nov; 24(21):5393-5399. PubMed ID: 27658790
[TBL] [Abstract][Full Text] [Related]
12. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
13. Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides.
Egorova A; Bogacheva M; Shubina A; Baranov V; Kiselev A
J Gene Med; 2014; 16(11-12):336-51. PubMed ID: 25382058
[TBL] [Abstract][Full Text] [Related]
14. Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.
Mona CE; Besserer-Offroy É; Cabana J; Lefrançois M; Boulais PE; Lefebvre MR; Leduc R; Lavigne P; Heveker N; Marsault É; Escher E
J Med Chem; 2016 Aug; 59(16):7512-24. PubMed ID: 27434274
[TBL] [Abstract][Full Text] [Related]
15. Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors.
Liu N; Wan Q; Cheng Z; Chen Y
Curr Top Med Chem; 2019; 19(1):17-32. PubMed ID: 30706786
[TBL] [Abstract][Full Text] [Related]
16. Slamming the DOR on chemokine receptor signaling: heterodimerization silences ligand-occupied CXCR4 and delta-opioid receptors.
Hereld D; Jin T
Eur J Immunol; 2008 Feb; 38(2):334-7. PubMed ID: 18203136
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
18. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor.
Våbenø J; Nikiforovich GV; Marshall GR
Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of leukocyte CXCR4 expression by sulfatide: an L-selectin-dependent pathway on CD4+ T cells.
Duchesneau P; Gallagher E; Walcheck B; Waddell TK
Eur J Immunol; 2007 Oct; 37(10):2949-60. PubMed ID: 17853408
[TBL] [Abstract][Full Text] [Related]
20. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
